OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Picking up again 9%+

Yes noted. Long may it continue.

Spoke to soon 7%

lol. upward trend though

:-)

Seems the rise in sp continues.

Nice to see one of my stocks travelling in the right direction!

Panmure Gordon says buy Dawnay Day Carpathian (LSE: DDC.L - news) (cutting the price target to 100p from 111p) Just Retirement (LSE: JR.L - news) (136p target price), Mears (340p target price), Misys (LSE: MSY.L - news) (166p target price), Oxford Biomedica (LSE: OXB.L - news) (69p target price),

Is this the cause or the reaction of the price rise?

You never know with analysts ie jumping on the band wagon.

For some time though analysts have tipped OXB to be a lot higher.

SP like many others, struggles to respond.

don't worry, sp will be over 50p this year IMO

Decided to sell and bank a nice profit.
Can't help feeling we could have a small downturn in general market now.

Have got these higher so I guess I'm covered if any offer does materialise.

AGM today - won't be able to make it alas.

Info today:

"LONDON (Thomson Financial) - Oxford Biomedica Plc, the UK gene medicine specialist, says performance from Jan 1 to May 8 this year is in line with management expectations, and sees its full-year sales in the range of 16-19 million pounds, up by about 140 pct compared with last year.

It says it has enough cash to support ongoing operations to the end of 2009, based on planned expenditure and without anticipating further milestone revenue from the collaboration with Sanofi-Aventis over its cancer drug TroVax.

In February this year the company announced that its cash position had been boosted by a 10 million euro TroVax milestone payment from Sanofi-Aventis."

Link to full RNS:

OXB Interim Management Statement

Shame this won't do what BLNX has just done. lol

Sales up by 140% is a nice stat :-)

I agree but the market seems to decide otherwise with sells outdoing buys by near 5 to 1 - Lets hope they are being collected for a big buyer. There is often a bit of tree shaking on a Friday

A lot of tree-shaking now...


Oxford Biomedica's phase III trial for cancer jab Trovax 'will not meet goals' - AFX

LONDON (Thomson Financial) - Oxford Biomedica Plc's cancer vaccination TroVax will not meet its defined goals in a late stage study for renal cancer, according to a key review board.

While the trial will continue, the Drug Safety Monitoring Board has ruled that there should be no more vaccinations administered.

Chief executive Mike McDonald said: 'This news is clearly disappointing. However, there is good reason to continue the study and potentially a late survival benefit for TroVax may still be demonstrated.'

The drug is being developed in partnership with Sanofi-Aventis SA.

Sold out a couple of weeks ago into SKP so no better off skp down 50% since I bought.

Of the two OXB Management is far better and focussed - but this blow may cause some heads to roll, although the progression of Trovax is still on-going. It's not as though OXB is a 1-product shop. It does mean we may see further falls as the trial unwinds. I have bought a few more as this is getting close to the cash-value. OXB bought another Oxford-based research Co abt a year ago and this should provide some additional products to undergo trials etc.etc.

Does anyone know if the US-trials are affected? -

Oxford Biomedica, the U.K. biotechnology company that is working with Sanofi-Aventis SA, had a record decline in London trading after saying its TroVax medicine won't meet the target of a kidney cancer study.

Oxford BioMedica fell 11 pence, or 59 percent, to 7.5 pence, giving the company a market value of 40.3 million pounds ($80.2 million). That's the biggest drop since the shares began trading in 1996. The stock has declined 71 percent this year.

Yes yes yes, I agree...that you say is fact - it's a nasty move for anyone with a million shares - not I . . . . . yet the Trial is continuing and as the ch Exec says:- ".... there is good reason to continue the study and potentially a late survival benefit for TroVax may still be demonstrated.'..."

Now, "he would say that"- - - springs to mind....yet this Friday RNS is not at all clear as to "why" the Trial is unsatisfactory - - - or "what went wrong", - and presumably we have to await further Data to establish if there is any real Value in Trovax.

I must say I'm very surprised as all earlier Trials indicated that not only was it good, it was ---very good.

Good luck.
I checked FT website and they are still reporting Feb.2008
- ah, happy days when the sp was close to 25p....

Its still valued at 40 million quid and no product ???

Bin bag job.